Jefferies Downgrades Amphastar Pharmaceuticals (AMPH), Cites Lack of Meaningful Upside Catalysts
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is one of the best drug stocks to buy according to analysts. Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals Inc. (AMPH)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Polaris Capital Management Bernard Horn | 43,232 | $846,915 | +22% | 0.07% |
| 2. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.26 | 1,000 | $20,260.00 | 13,151 | 2020-08-14 | Filing | |
| $16.06 | 15,000 | $240,853.50 | 2,080,619 | 2018-05-16 | Filing | |
| $16.08 | 25,000 | $401,970.00 | 2,065,619 | 2018-05-15 | Filing | |
| $10.84 | 6,000 | $65,022.00 | 101,215 | 2014-08-25 | Filing | |
| $10.00 | 3,500 | $34,999.65 | 17,639 | 2014-08-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.20 | 9,787 | $256,379.27 | 138,043 | 2025-12-17 | Filing | |
| $25.92 | 2,426 | $62,888.23 | 71,368 | 2025-12-12 | Filing | |
| $25.69 | 1,737 | $44,620.06 | 73,794 | 2025-12-11 | Filing | |
| $27.10 | 4,179 | $113,253.41 | 35,183 | 2025-11-25 | Filing | |
| $26.49 | 16,679 | $441,836.72 | 75,531 | 2025-11-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 66,931,000 | $60,639,486 | 1.4% | |
| 2. | 2,027,947 | $39,726,234 | 0.01% | |
| 3. | 1,543,655 | $30,240,201 | 0% | |
| 4. | 944,789 | $18,508,417 | 0.15% | |
| 5. | 787,816 | $15,433,315 | 0% |
News See All
9 Best Drug Stocks to Buy According to Analysts
On April 27, Jurrien Timmer, director of global macro at Fidelity Investments, appeared on CNBC to talk about the market and oil prices, and how necessary it is for oil prices to retreat from their highs...
Wells Fargo Sees Amphastar Pharmaceuticals, Inc.'s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth
TheFly reported on February 27 that Wells Fargo reduced its price target on AMPH to $30 from $34 and kept an Overweight rating on the shares.
12 Most Promising Small-Cap Stocks According to Wall Street Analysts
Small-cap stocks are drawing renewed investor attention in 2026 as capital rotates away from years of concentration in mega-cap names.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2025 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2025 Earnings Call Transcript February 26, 2026Amphastar Pharmaceuticals, Inc. misses on earnings expectations.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q3 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Amphastar Pharmaceuticals, Inc. Third Quarter Earnings Call.
Amphastar Pharmaceuticals, Inc. (AMPH) Secures FDA Approval for Generic Iron Sucrose Injection
Amphastar Pharmaceuticals, Inc.
11 Best Pharma Stocks to Invest in for the Long Term
According to a recent White House announcement, President Trump wrote letters to 17 major pharmaceutical companies outlining the actions they could take to bring the prices of prescription pharmaceuticals...
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q2 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Amphastar Pharmaceuticals' Second Quarter Earnings Call.
JPMorgan Downgrades Amphastar Pharmaceuticals (AMPH) to Neutral from Overweight, Brings PT Down to $30
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On May 12, JPMorgan downgraded Amphastar Pharmaceuticals, Inc.